Sophia Goodridge, MD
Urology · Roswell, GANPI 1255690905
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Urovant Sciences Inc at 41.3% of the total.
Across 155 payments — averaging $118.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urovant Sciences Inc$8K
- Medtronic$6K
- Axonics, Inc.$1K
- Boston Scientific$1K
- Teleflex LLC$213
- Sumitomo Pharma America, Inc.$206
- plus $2K from 26 others
Across 2 payments — averaging $621.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1K
What the payments were for
- Speaking & faculty fees$8,43746%
- Travel & lodging$4,43324%
- Food & beverage$5,46130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urovant Sciences Inc | 13 | $7,570 |
| Medtronic(2 entities) | 44 | $6,106 |
| Axonics, Inc. | 7 | $1,366 |
| Boston Scientific | 22 | $1,207 |
| Teleflex LLC | 3 | $213 |
| Sumitomo Pharma America, Inc. | 6 | $206 |
| Endo Pharmaceuticals Inc. | 10 | $191 |
| Coloplast | 5 | $162 |
| Olympus America Inc. | 3 | $161 |
| Ambu Inc. | 4 | $149 |
| Dendreon Pharmaceuticals LLC | 2 | $145 |
| Neotract Inc. | 4 | $99 |
| Tolmar, Inc. | 3 | $79 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $76 |
| Blue Earth Diagnostics | 3 | $75 |
| Myovant Sciences Inc. | 2 | $52 |
| Agiliti Surgical, Inc. | 2 | $45 |
| ABC Home Medical Supply, Inc. | 2 | $43 |
| Laborie Medical Technologies Corp. | 2 | $39 |
| Procept Biorobotics Corporation | 2 | $39 |
| Angiodynamics, Inc. | 1 | $38 |
| Bluewind Medical | 1 | $34 |
| Vertex | 1 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| 180 Medical, Inc. | 1 | $30 |
| Merck | 1 | $27 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| BD | 1 | $19 |
| Aroa Biosurgery Incorporated | 1 | $18 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,331 in reported general payments places this provider in the 85th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 137 | $96,406 |
| MyrbetriqMirabegron | 56 | $34,761 |
| Estradiol | 94 | $5,735 |
| Trospium Chloride | 26 | $1,603 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 39 | $778 |
| Desmopressin Acetate | 18 | $593 |
| Tamsulosin Hcl | 55 | $543 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 86 | $388 |
| Cefdinir | 15 | $167 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 54 | $152 |
| Oxycodone Hcl | 47 | $128 |
| Levofloxacin | 19 | $83 |
| Fluconazole | 17 | $82 |
| Ciprofloxacin Hcl | 17 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $206 | $96,406137 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $34,76156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 369 urology providers in Georgia.
Other urology in Roswell
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Scott MillerRoswell$85K
- Akash KapadiaRoswell$63K
- Daniel BelewRoswell$16K
- Rutveej PatelRoswell$15K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.